Realm Therapeutics (RLM) reports alongside FY16 financial results that its clinical pipeline is advancing to plan. RLM also confirms that both of its lead candidates - PR022, a novel high concentration formulation of hypochlorous acid (HOCl) to treat Atopic Dermatitis (AD) and PR013 to treat Allergic Conjunctivitis (AC) - will move into Phase II studies in 2017. Consequently, top line data readouts for both candidates is anticipated during H118. The novel topical treatments aim to provide efficacious and safer alternatives to standard treatments in both indications providing significant commercial potential. The year end 2016 cash position of $21m provides funding to cover the first Phase II study in each indication.
27 Mar 2017
Moving to the timelines
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Moving to the timelines
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
27 Mar 2017 -
Author:
Emma Ulker -
Pages:
2
Realm Therapeutics (RLM) reports alongside FY16 financial results that its clinical pipeline is advancing to plan. RLM also confirms that both of its lead candidates - PR022, a novel high concentration formulation of hypochlorous acid (HOCl) to treat Atopic Dermatitis (AD) and PR013 to treat Allergic Conjunctivitis (AC) - will move into Phase II studies in 2017. Consequently, top line data readouts for both candidates is anticipated during H118. The novel topical treatments aim to provide efficacious and safer alternatives to standard treatments in both indications providing significant commercial potential. The year end 2016 cash position of $21m provides funding to cover the first Phase II study in each indication.